FY2026 EPS Estimate for Aethlon Medical Decreased by Analyst

Aethlon Medical, Inc. (NASDAQ:AEMD) – Equities research analysts at Zacks Research cut their FY2026 EPS estimates for shares of Aethlon Medical in a research report issued to clients and investors on Wednesday, February 18th. Zacks Research analyst M. Marin now forecasts that the medical equipment provider will post earnings per share of ($10.40) for the year, down from their prior estimate of ($9.41). The consensus estimate for Aethlon Medical’s current full-year earnings is ($0.73) per share. Zacks Research also issued estimates for Aethlon Medical’s Q4 2026 earnings at ($2.47) EPS.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings data on Thursday, February 12th. The medical equipment provider reported ($2.45) EPS for the quarter, missing the consensus estimate of ($2.01) by ($0.44).

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $560.00.

Aethlon Medical Price Performance

NASDAQ AEMD opened at $2.01 on Friday. Aethlon Medical has a 1 year low of $1.86 and a 1 year high of $49.58. The company has a fifty day moving average of $2.56 and a 200 day moving average of $5.88. The company has a market capitalization of $2.65 million, a PE ratio of -0.14 and a beta of 1.60.

Institutional Investors Weigh In On Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC purchased a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical at the end of the most recent reporting period. Institutional investors and hedge funds own 1.99% of the company’s stock.

Key Stories Impacting Aethlon Medical

Here are the key news stories impacting Aethlon Medical this week:

• Positive Sentiment: HC Wainwright raised several multi‑quarter and multi‑year EPS forecasts (FY2027–FY2030 and a series of 2027 quarterly forecasts), signaling the firm expects gradually improved results over the medium term. This could support sentiment if Aethlon executes on its plan. HC Wainwright estimate changes
• Neutral Sentiment: A shareholder/analyst call prepared remarks transcript was published (useful for detail on strategy, pipeline and management commentary) — may inform investors but contains no immediate market-moving announcement. Shareholder/Analyst Call Transcript
• Neutral Sentiment: Daily short-interest notices flagged a “large increase” in February but the reported short‑interest figure is 0 shares and days‑to‑cover shows 0.0 — the data look inconsistent/possibly erroneous, so there is no clear short‑squeeze or added short pressure indicated by these notices.
• Negative Sentiment: Zacks Research lowered Q4 2026 and FY2026 EPS estimates materially (Q4 to roughly ($2.47) and FY2026 to ($10.40) in their model), reducing near‑term expectations and adding short‑term negative pressure on sentiment. Zacks estimate cuts
• Negative Sentiment: Recent quarterly results showed a significant EPS miss (AEMD reported a large loss vs. consensus), and consensus full‑year estimates remain negative — these fundamentals help explain continued selling pressure and depressed valuation metrics.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.